Expression of miR-664 and miR-184 on proliferation, apoptosis and migration of osteosarcoma cells

Tao,Pengfei; Feng,Jing; Li,Qiong; Liu,Wei; Yang,Lin; Zhao,Xiaolong; Ni,Huan; Xia,Ping

doi:10.3892/ol.2018.9739

Expression of miR-664 and miR-184 on proliferation, apoptosis and migration of osteosarcoma cells

Authors:
- Pengfei Tao
- Jing Feng
- Qiong Li
- Wei Liu
- Lin Yang
- Xiaolong Zhao
- Huan Ni
- Ping Xia
View Affiliations

Affiliations: Department of Spine Surgery, Wuhan No. 1 Hospital, Wuhan, Hubei 430022, P.R. China, Department of Radiology, Taihe Hospital Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China
Published online on: November 20, 2018 https://doi.org/10.3892/ol.2018.9739
Pages: 1791-1797
Copyright: © Tao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression of micro-ribonucleic acid miR-664 and miR-184 on the biological characteristics of osteosarcoma (OS) SOSP-9607 cells was investigated. Eighteen surgical specimens of OS and 18 normal tissue specimens were collected. The expression of miR-664 and miR-184 was detected via fluorescence reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The OS cell line SOSP-9607 was selected as the object of study, and miR-664 blank group, miR-664 mimic group, miR-664 inhibitor group, miR-184 blank group, miR-184 mimic group and miR-184 inhibitor group were established through transfection. Changes in apoptosis were detected via flow cytometry, the cell proliferation capacity was detected via Cell Counting Kit-8 assay, and the cell migration was observed via wound healing assay. In cancer tissues of OS patients, the relative expression of miR-664 and miR-184 was significantly higher than that in para-carcinoma tissues (P<0.05). The cell growth in miR-664 inhibitor group was obviously decreased compared with those in miR-664 blank and mimic groups (P<0.05). There were differences in the cell migration capacity among groups (P<0.01), and the cell scratch areas in miR-664 and miR-184 mimic groups were significantly decreased compared with those in miR-664 and miR-184 blank groups (P<0.05), while they were significantly increased in miR-664 and miR-184 inhibitor groups compared with those in miR-664 and miR-184 blank and mimic groups (P<0.05, P<0.01). There were differences in the apoptosis rate among groups (P<0.01) and apoptosis in miR-664 and miR-184 inhibitor groups was remarkably increased compared with those in miR-664 and miR-184 blank and mimic groups (P<0.05). Downregulating the expression of miR-664 and miR-184 may promote apoptosis, inhibit the proliferation and reduce the migration capacity of SOSP-9607 cells. Therefore, miR-664 and miR-184 may provide a theoretical basis for the target selection in clinical targeted therapy and drug development for OS.

View Figures

View References

1	Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
2	Lagmay JP, Krailo MD, Dang H, Kim A, Hawkins DS, Beaty O 3rd, Widemann BC, Zwerdling T, Bomgaars L, Langevin AM, et al: Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials through Children's cancer group, Pediatric oncology group, and Children's oncology group: Learning from the past to move forward. J Clin Oncol. 34:3031–3038. 2016. View Article : Google Scholar : PubMed/NCBI
3	Daw NC, Chou AJ, Jaffe N, Rao BN, Billups CA, Rodriguez-Galindo C, Meyers PA and Huh WW: Recurrent osteosarcoma with a single pulmonary metastasis: A multi-institutional review. Br J Cancer. 112:278–282. 2015. View Article : Google Scholar : PubMed/NCBI
4	Subbiah V, Anderson P and Rohren E: Alpha emitter radium 223 in high-risk osteosarcoma: First clinical evidence of response and blood-brain barrier penetration. JAMA Oncol. 1:253–255. 2015. View Article : Google Scholar : PubMed/NCBI
5	Li J, Yang Z, Li Y, Xia J, Li D, Li H, Ren M, Liao Y, Yu S, Chen Y, et al: Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment. Oncotarget. 7:44763–44778. 2016.PubMed/NCBI
6	Bandara KV, Michael MZ and Gleadle JM: MicroRNA biogenesis in hypoxia. MicroRNA. 6:80–96. 2017. View Article : Google Scholar : PubMed/NCBI
7	Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Rådmark O, Kim S, et al: The nuclear RNase III Drosha initiates microRNA processing. Nature. 425:415–419. 2003. View Article : Google Scholar : PubMed/NCBI
8	Park JK, Peng H, Yang W, Katsnelson J, Volpert O and Lavker RM: miR-184 exhibits angiostatic properties via regulation of Akt and VEGF signaling pathways. FASEB J. 31:256–265. 2017. View Article : Google Scholar : PubMed/NCBI
9	Wu L, Li Y, Li J and Ma D: MicroRNA-664 targets insulin receptor substrate 1 to suppress cell proliferation and invasion in breast cancer. Oncol Res. 2018.(Epub ahead of print). https://doi.org/10.3727/096504018X15193500663936 View Article : Google Scholar
10	Picci P: Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2:62007. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
12	Isakoff MS, Bielack SS, Meltzer P and Gorlick R: Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
13	Faisham WI, Saad Mat AZ, Alsaigh LN, Azman Nor MZ, Kamarul Imran M, Biswal BM, Bhavaraju VM, Salzihan MS, Hasnan J, Ezane AM, et al: Prognostic factors and survival rate of osteosarcoma: A single-institution study. Asia Pac J Clin Oncol. 13:e104–e110. 2017. View Article : Google Scholar : PubMed/NCBI
14	Chen YU, Xu SF, Xu M and Yu XC: Postoperative infection and survival in osteosarcoma patients: Reconsideration of immunotherapy for osteosarcoma. Mol Clin Oncol. 3:495–500. 2015. View Article : Google Scholar : PubMed/NCBI
15	Qi Y, Zhao C, Li H, Zhang B, Tada K, Abe H and Tada M: Genetic variations in interleukin-6 polymorphism and the association with susceptibility and overall survival of osteosarcoma. Tumour Biol. 37:9807–9811. 2016. View Article : Google Scholar : PubMed/NCBI
16	Suzuki HI, Young RA and Sharp PA: Super-enhancer-mediated RNA processing revealed by integrative microRNA network analysis. Cell. 168(1000–1014): e152017.
17	Chang TH, Tsai MF, Gow CH, Wu SG, Liu YN, Chang YL, Yu SL, Tsai HC, Lin SW, Chen YW, et al: Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C. Cancer Lett. 402:190–202. 2017. View Article : Google Scholar : PubMed/NCBI
18	Yu L, Wu D, Gao H, Balic JJ, Tsykin A, Han TS, Liu YD, Kennedy CL, Li JK, Mao JQ, et al: Clinical utility of a STAT3-regulated miRNA-200 family signature with prognostic potential in early gastric cancer. Clin Cancer Res. 24:1459–1472. 2018. View Article : Google Scholar : PubMed/NCBI
19	Li Y, Zhang M, Chen H, Dong Z, Ganapathy V, Thangaraju M and Huang S: Ratio of miR-196s to HOXC8 messenger RNA correlates with breast cancer cell migration and metastasis. Cancer Res. 70:7894–7904. 2010. View Article : Google Scholar : PubMed/NCBI
20	Yang H, Cho ME, Li TW, Peng H, Ko KS, Mato JM and Lu SC: MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma. J Clin Invest. 123:285–298. 2013. View Article : Google Scholar : PubMed/NCBI
21	Park KS, Moon YW, Raffeld M, Lee DH, Wang Y and Giaccone G: High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer. Lung Cancer. 116:38–45. 2018. View Article : Google Scholar : PubMed/NCBI
22	Simonian M, Mosallayi M and Mirzaei H: Circulating miR-21 as novel biomarker in gastric cancer: Diagnostic and prognostic biomarker. J Cancer Res Ther. 14:4752018.PubMed/NCBI
23	Bao Y, Chen B, Wu Q, Hu K, Xi X, Zhu W, Zhong X and Chen J: Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7. Clin Exp Med. 17:51–58. 2017. View Article : Google Scholar : PubMed/NCBI
24	Ma C, Wei F, Xia H, Liu H, Dong X, Zhang Y, Luo Q, Liu Y and Li Y: MicroRNA-10b mediates TGF-β1-regulated glioblastoma proliferation, migration and epithelial-mesenchymal transition. Int J Oncol. 50:1739–1748. 2017. View Article : Google Scholar : PubMed/NCBI
25	Lin BC, Huang D, Yu CQ, Mou Y, Liu YH, Zhang DW and Shi FJ: MicroRNA-184 modulates doxorubicin resistance in osteosarcoma cells by targeting BCL2L1. Med Sci Monit. 22:1761–1765. 2016. View Article : Google Scholar : PubMed/NCBI